Literature DB >> 20620113

Viral vector-mediated RNA interference.

Linda B Couto1, Katherine A High.   

Abstract

RNA interference (RNAi) is a powerful gene silencing mechanism that if properly harnessed has the potential to revolutionize medical interventions. Delivery of inhibitory RNAs to target tissues needs to be safe, efficient, and for many diseases, long-lasting, in order to exploit this endogenous mechanism for therapeutic purposes. Viral vector systems, based on adeno-associated viruses and lentiviruses, are ideally suited to mediate RNAi because they can safely transduce a wide range of tissues and provide sustained levels of gene expression. There are now many examples of the use of viral vector-mediated RNAi to inhibit gene expression in animal models of disease, and in many cases proof-of-principle has been demonstrated. The efficient delivery of RNAi has also uncovered a number of concerns that raise questions regarding the clinical application of this technology, including off-target effects, innate immune responses, and alterations in the endogenous microRNA (miRNA) pathway. However, over the past several years, work has been done to address these problems and a number of solutions are now being implemented to mitigate these potential risks. With a deeper understanding of RNAi and continued progress in designing RNAi effectors, viral vector-mediated RNAi has the potential to change the way many diseases are treated.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20620113     DOI: 10.1016/j.coph.2010.06.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  41 in total

1.  Nanoparticle-mediated down-regulation of TWIST increases radiosensitivity of nasopharyngeal carcinoma cells via ERK pathway.

Authors:  Xianlu Zhuo; Aoshuang Chang; Chuang Huang; Li Yang; Houyu Zhao; Yongzhong Wu; Qi Zhou
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

2.  Analysis of CCN4 Function in Osteogenic and Osteoclastic Cells Using Gain and Loss of Function Approaches.

Authors:  Azusa Maeda; Marian Young; Mitsuaki Ono
Journal:  Methods Mol Biol       Date:  2017

Review 3.  Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.

Authors:  Fang Liu; Chunfang Wang; Yuantao Gao; Xiao Li; Feng Tian; Yongtao Zhang; Mingyang Fu; Pengfei Li; Yali Wang; Fei Wang
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

4.  Pseudo-typed Semliki Forest virus delivers EGFP into neurons.

Authors:  Fan Jia; Huan Miao; Xutao Zhu; Fuqiang Xu
Journal:  J Neurovirol       Date:  2016-10-13       Impact factor: 2.643

5.  Stereotaxic injection of a viral vector for conditional gene manipulation in the mouse spinal cord.

Authors:  Perrine Inquimbert; Martin Moll; Tatsuro Kohno; Joachim Scholz
Journal:  J Vis Exp       Date:  2013-03-18       Impact factor: 1.355

6.  An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.

Authors:  Christina E Khodr; Mohan K Sapru; Jyothi Pedapati; Ye Han; Neva C West; Adrian P Kells; Krystof S Bankiewicz; Martha C Bohn
Journal:  Brain Res       Date:  2011-04-22       Impact factor: 3.252

Review 7.  Tailoring the RNAi efficiency of polyplexes.

Authors:  Weiqi Zhang; Haiyan Xu
Journal:  Bioengineered       Date:  2014-02-03       Impact factor: 3.269

8.  TRAF6 upregulation in spinal astrocytes maintains neuropathic pain by integrating TNF-α and IL-1β signaling.

Authors:  Ying Lu; Bao-Chun Jiang; De-Li Cao; Zhi-Jun Zhang; Xin Zhang; Ru-Rong Ji; Yong-Jing Gao
Journal:  Pain       Date:  2014-10-19       Impact factor: 6.961

9.  rna interference targeting p110β reduces tumor necrosis factor-alpha production in cellular response to wear particles in vitro and osteolysis in vivo.

Authors:  Jian-bin Huang; Yue Ding; Dong-sheng Huang; Wei-ke Zeng; Zhi-ping Guan; Mao-lin Zhang
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

10.  Dendronized gold nanoparticles for siRNA delivery.

Authors:  Sung Tae Kim; Apiwat Chompoosor; Yi-Cheun Yeh; Sarit S Agasti; David J Solfiell; Vincent M Rotello
Journal:  Small       Date:  2012-08-08       Impact factor: 13.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.